Literature DB >> 21497171

Electrolytic lesions of the bed nucleus of the stria terminalis disrupt freezing and startle potentiation in a conditioned context.

Laura Luyten1, Kris van Kuyck, Debora Vansteenwegen, Bart Nuttin.   

Abstract

Expression of contextual anxiety in a previously shocked context is a widely used model of anxiety, with the main behavioral measures being freezing or startle amplitude. There is extensive evidence that the bed nucleus of the stria terminalis (BST) is involved in several anxiety paradigms, e.g., BST lesions disrupt contextual freezing. Surprisingly, studies investigating the effect on startle potentiation in a conditioned context are still lacking in the literature. In the present study, we found that post-training bilateral electrolytic lesions in the BST completely disrupted the expression of contextual anxiety, as quantified with combined measurements of startle amplitude and freezing.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21497171     DOI: 10.1016/j.bbr.2011.03.066

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  14 in total

1.  Threat imminence dictates the role of the bed nucleus of the stria terminalis in contextual fear.

Authors:  Travis D Goode; Gillian M Acca; Stephen Maren
Journal:  Neurobiol Learn Mem       Date:  2019-11-15       Impact factor: 2.877

2.  Enhanced discrimination between threatening and safe contexts in high-anxious individuals.

Authors:  Evelyn Glotzbach-Schoon; Regina Tadda; Marta Andreatta; Christian Tröger; Heike Ewald; Christian Grillon; Paul Pauli; Andreas Mühlberger
Journal:  Biol Psychol       Date:  2013-02-04       Impact factor: 3.251

3.  The bed nucleus of the stria terminalis is critical for anxiety-related behavior evoked by CO2 and acidosis.

Authors:  Rebecca J Taugher; Yuan Lu; Yimo Wang; Collin J Kreple; Ali Ghobbeh; Rong Fan; Levi P Sowers; John A Wemmie
Journal:  J Neurosci       Date:  2014-07-30       Impact factor: 6.167

4.  Electrical stimulation in the bed nucleus of the stria terminalis alleviates severe obsessive-compulsive disorder.

Authors:  L Luyten; S Hendrickx; S Raymaekers; L Gabriëls; B Nuttin
Journal:  Mol Psychiatry       Date:  2015-08-25       Impact factor: 15.992

5.  Role of bed nucleus of the stria terminalis and amygdala AMPA receptors in the development and expression of context conditioning and sensitization of startle by prior shock.

Authors:  Michael Davis; David L Walker
Journal:  Brain Struct Funct       Date:  2013-08-11       Impact factor: 3.270

6.  It takes two: Bilateral bed nuclei of the stria terminalis mediate the expression of contextual fear, but not of moderate cued fear.

Authors:  Kelly Luyck; Lutgarde Arckens; Bart Nuttin; Laura Luyten
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-03-10       Impact factor: 5.067

7.  Can electrical stimulation of the human bed nucleus of the stria terminalis reduce contextual anxiety? An unanswered question.

Authors:  Kelly Luyck; Laura Luyten
Journal:  Front Behav Neurosci       Date:  2015-03-17       Impact factor: 3.558

8.  CGRP antagonist infused into the bed nucleus of the stria terminalis impairs the acquisition and expression of context but not discretely cued fear.

Authors:  Kelly S Sink; Michael Davis; David L Walker
Journal:  Learn Mem       Date:  2013-11-19       Impact factor: 2.460

9.  Contextual fear conditioning in virtual reality is affected by 5HTTLPR and NPSR1 polymorphisms: effects on fear-potentiated startle.

Authors:  Evelyn Glotzbach-Schoon; Marta Andreatta; Andreas Reif; Heike Ewald; Christian Tröger; Christian Baumann; Jürgen Deckert; Andreas Mühlberger; Paul Pauli
Journal:  Front Behav Neurosci       Date:  2013-04-23       Impact factor: 3.558

10.  Electrolytic post-training lesions of the bed nucleus of the stria terminalis block startle potentiation in a cued fear conditioning procedure.

Authors:  Kelly Luyck; Bart Nuttin; Laura Luyten
Journal:  Brain Struct Funct       Date:  2017-12-16       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.